Cognitive deficits associated with schizophrenia (CDS) are implicated as a core symptom cluster of the disease and are associated with poor daily life functioning. Unfortunately, current antipsychotic agents provide little alleviation of CDS, representing a critical unmet therapeutic need. Here we investigated the effects of ABT-239 and A-431404, non-imidazole histamine H 3 receptor (H 3 R) antagonists, in animal models with relevance to CDS. As N-methyl-D-aspartate receptor hypofunction is considered an important factor in the pathogenesis of schizophrenia, acute administration of ketamine or MK-801 was used to induce cognitive impairments. The assays employed in the current studies were spontaneous alternation in cross-maze, used as an indication of working memory, and inhibitory avoidance (IA), used to assess long-term memory retention. Risperidone and olanzapine were also tested to directly compare the effects of H 3 R antagonists to two widely used antipsychotics. ABT-239 and A-431404, but not risperidone and olanzapine, attenuated ketamine-induced deficits on spontaneous alternation in cross-maze, while none of these compounds affected alternation performance on their own. ABT-239 and A-431404 also attenuated MK-801-induced impairments in IA ; no effects were observed when given alone. Risperidone and olanzapine, however, failed to attenuate MK-801-induced deficits in IA and produced dose-dependent impairments when given alone. ABT-239 was also investigated in methylazoxymethanol acetate (MAM) treated rats, a neurodevelopmental model for schizophrenia. Chronic, but not acute, treatment with ABT-239 significantly improved spontaneous alternation impairments in MAM rats tested in cross-maze. In summary, these results suggest H 3 R antagonists may have the potential to ameliorate CDS.
Introduction
Schizophrenia is a debilitating, heterogeneous mental illness that affects about 1 % of the worldwide population (Rossler et al. 2005) . Patients who suffer from this chronic disease display neurobehavioural impairments that fall into three main symptom clusters : positive symptoms ; negative symptoms ; cognitive deficits. The last symptom cluster, cognitive deficits associated with schizophrenia (CDS), is pervasive, affecting about 75-80 % of patients, and has been found to be a better predictor of socio-vocational functional outcomes than the presence or severity of positive symptoms (Green et al. 2000 ; Velligan et al. 2000) . Schizophrenia patients typically perform 1-2 S.D. below healthy populations on neurocognitive measures of executive function, working memory and attention (Heinrichs & Zakzanis, 1998) . Although atypical antipsychotics ameliorate positive symptoms in most patients, they have no or only moderate effects on cognition (Keefe et al. 2007) . As a result, there is a great clinical need for the discovery and development of novel therapeutics.
The exact aetiology of schizophrenia has remained elusive despite decades of dedicated investigation. The glutamate hypothesis of schizophrenia has gained acceptance (Coyle, 2006 ; Krystal et al. 2003 ; Olney & Farber, 1995) and is based on the observation that N-methyl-D-aspartate receptor (NMDAR) antagonists, such as PCP and ketamine, induce schizophrenia-like behaviours and cognitive impairments in healthy humans and exacerbate symptoms in schizophrenic patients (Ghoneim et al. 1985 ; Javitt & Zukin, 1991 ; Krystal et al. 1994 ; Luby et al. 1959 ; Malhotra et al. 1997) . In healthy humans, sub-anaesthetic doses of ketamine produce deficits in attention and working memory (Adler et al. 1998 ; Krystal et al. 1994 ; Malhotra et al. 1996 ; Rowland et al. 2005) , much like those seen in patients. NMDAR antagonists also produce schizophrenia-like behavioural disturbances in rodents and, importantly for CDS research, impair neurocognition (for review see Large, 2007) . Therefore, the use of NMDAR antagonists preclinically represents a potentially important model for screening novel agents to treat CDS.
Neurodevelopmental dysfunction has also been proposed to play a critical role in the aetiology of schizophrenia (for review see Fatemi & Folsom, 2009 ). Several lines of evidence suggest that obstetric complications and perinatal disturbances increase the risk of developing schizophrenia (Marenco & Weinberger, 2000) . Genetic association studies have also indicated disruption in genes critical for neural development and connectivity (Harrison & Weinberger, 2005) . Preclinically, numerous rodent models have been developed to capture aspects of the neurodevelopmental basis of schizophrenia (Jaaro-Peled, 2009 ; Rehn & Rees, 2005 ; Tseng et al. 2009 ). The methylazoxymethanol acetate (MAM) neurodevelopmental model of schizophrenia is a prenatal pharmacological insult model that has been well characterized (for review, see ). In this model, MAM, a methylating agent that disrupts neurogenesis, is administered prenatally to disrupt neural development. Offspring who are exposed to MAM in utero develop brain morphological abnormalities similar to those seen in schizophrenia, including enlarged lateral ventricles and decreased hippocampal volume (Chin et al. 2010) . MAM animals also show impairments in attention and working memory (Flagstad et al. 2005 ; Le Pen et al. 2006 ; Moore et al. 2006) , as well as in other behavioural domains that model aspects of schizophrenia (for review, see ). Therefore, it may be a relevant preclinical model for CDS.
H 3 R antagonists have been identified as a promising target for CDS and may have potential as a novel therapeutic (Brioni et al. 2010) . The H 3 receptor can function as an auto-and hetero-receptor to modulate the synthesis and release of multiple neurotransmitters critical for cognition, including histamine, dopamine and acetylcholine (Brioni et al. 2010) . Furthermore, H 3 R-containing neurons project to the prefrontal cortex and hippocampus (Drutel et al. 2001 ), brain areas essential for learning and memory. H 3 R antagonists enhance multiple domains of cognition in naive animals (for review, see Esbenshade et al. 2008 ), but only a limited number of studies have investigated H 3 R antagonists in models relevant to CDS (Bardgett et al. 2010 ; Bernaerts et al. 2004 ; Charlier & Tirelli, 2011 ; Chen et al. 1999 ; Huang et al. 2004 ; Nishiga & Kamei, 2003) . All of these studies used imidazolebased tool compounds (e.g. thioperamide or ciproxifan), which are undesirable for clinical development due to cytochrome P450 inhibition and low brain penetration (Esbenshade et al. 2006) . The goals of the current studies were to investigate and directly compare the effects of ABT-239 and A-431404, potent non-imidazole-based H 3 R antagonists, to atypical antipsychotics in preclinical models for CDS. ABT-239 and A-431404 have a high affinity for both human and rat H 3 R (1.2 and 0.45 nM for ABT-239 and 1.0 and 0.27 nM for A-431404, respectively) and demonstrate >100-fold selectivity for H 3 R compared to H 1 , H 2 , H 4 receptors, a2A and a2C receptors and 5-HT 3 receptors Zhang et al. 2005) . Doses were chosen based on previous work performed internally in rodent cognition models .
Materials and method

Animals
Male Long-Evans rats (Charles River Laboratories, USA), weighing between 330 and 450 g, were used for cross-maze experiments evaluating drug-induced effects in ketamine-and non-ketamine-treated subjects. For MAM cross-maze experiments, pregnant SpragueDawley dams (Charles Rivers) were acquired on gestational day 10. On gestational day 17, dams were administered either saline or 25 mg/kg MAM i.p. The female offspring were subsequently weaned at postnatal day 21 and later tested in cross-maze beginning at age 19 wk. Females were used as they demonstrated more robust and consistent behavioural impairments compared to males (Basso et al. 2010) . Male CD1/ICR mice (Charles River Laboratories), weighing between 30 and 40 g, were used for inhibitory avoidance (IA) experiments. All animals were group-housed in climate-controlled rooms and maintained on a 12 h light/dark cycle (lights on 06 : 00 hours). Food and water were available ad libitum except during behavioural testing. Testing was conducted between 12 : 00 and 16 : 00 hours. All experiments were approved by the Abbott Laboratories Institutional Animal Care and Use Committee and conducted in a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care.
Drugs
Racemic ketamine hydrochloride (Fort Dodge Animal Health, USA), (+)-MK-801 hydrogen maleate (Research Biochemical International, USA) and ABT-239 (synthesized at Abbott Laboratories, USA) were dissolved in sterile water. MAM (Midwest Research Institute, USA) was dissolved in sterile saline. A-431404 (synthesized at Abbott Laboratories), olanzapine (Sigma Chemical Co., USA) and risperidone (MP Biomedicals, USA) were dissolved in 0.3 % tartaric acid and pH adjusted to 4.0-5.0 with NaOH. Compounds were dosed at a volume of 1 ml/kg for rat and 10 ml/kg for mouse.
Ketamine was used to induce cognitive impairments in the cross-maze model, while MK-801 was used in IA. The rationale for using different NDMAR antagonists in these models was twofold : MK-801 is a more selective NMDAR antagonist compared to ketamine and thus may be a better choice to use when modelling the NMDA-based hypothesis for schizophrenia ; ketamine, however, may represent a better translational tool given that it can be used in humans for exploratory research. In order to address these two purposes, both MK-801 and ketamine were used.
Cross-maze model to assess spatial working memory
Rats were brought to the cross-maze room 2 h before testing in order to acclimatize to the environment. The cross-maze consisted of four arms constructed of black moulded plastic with the following dimensions (55 cm lengthr10 cm widthr15 cm height). Extra-maze spatial cues, consisting of various geometric shapes made with black electric tape, were placed on the four walls of the testing room.
For experiments performed in the ketamineinduced deficit model, .0 mg/kg), A-431404 (0.3-3.0 mg/kg), risperidone (0.03-0.3 mg/ kg) and olanzapine (0.1-1 mg/kg) were administered i.p. 30 min before testing. Ketamine (4 mg/kg) was given subcutaneously 15 min later. This dose of ketamine was chosen as it produced an approximate 50 % reduction in spontaneous alternation performance with minimal motoric effects, based upon a doseresponse study performed internally (data not shown). Following drug administration, rats were placed into the end of a randomly selected arm with their head facing away from the centre of the maze. They were then allowed to freely explore the maze for 7 min while the sequence of arms entered was recorded by hand. The raw sequence was used to calculate parameters of spatial working memory (arm alternations) and general locomotor activity (arm entries). An alternation was defined as four consecutive entries into four different arms. Percent alternation was then calculated using the formula : (total alternations/(total arm entriesx3))r100. Arm entries were counted when both hind paws crossed the entrance of a newly entered arm. Subjects that made <10 total arm entries were excluded from analysis.
For experiments performed in non-ketaminetreated subjects, the exact same protocol was used, except subjects did not receive challenge with ketamine.
Inhibitory avoidance model of long-term memory
Mice were brought to the IA room 2 h prior to training and testing sessions for acclimatization. The room was dimly lit. Experiments were performed on two consecutive days : mice were trained on the first day (training day) and then tested 24 h later for long-term memory retention (test day).
For experiments performed in the MK-801-induced deficit model, .0 mg/kg), A-431404 (0.3-3.0 mg/kg), risperidone (0.03-0.3 mg/kg) and olanzapine (0.3-3.0 mg/kg) were administered i.p. 40 min before training. MK-801 (0.1 mg/kg) was then administered i.p. 20 min later. This dose of MK-801 was used, as a dose-response study performed internally (data not shown) indicated that 0.1 mg/kg produced a robust impairment on memory retention, as illustrated by >50 % reduction in test day transfer latencies, while having minimal motoric effects (e.g. hyperactivity). Following drug administration, a mouse was then placed into the illuminated side of a two-chambered shuttle box (passive avoidance box ; Ugo Basile, Italy), with its head facing away from the door, and a timer was activated. Mice were given 30 s to explore the illuminated chamber before the door to the opposing dark chamber was automatically opened. Five seconds after a mouse completely crossed into the dark chamber, the door closed and foot shock was applied (0.3 mA, 1 s duration). If a mouse did not cross within 60 s after the door opened, it was excluded from the study. For experiments with risperidone and olanzapine, mice were given an additional 120 s (or 180 s total) to cross into the dark chamber. This was done to accommodate increased transfer latencies due to sedative side-effects produced by higher doses of these antipsychotics. Mice that did not independently cross within 120 s were gently guided to cross by hand into the adjoining dark chamber. Only three total subjects (two treated with 0.3 mg/kg risperidone and one treated with 3 mg/kg olanzapine) required assistance. Mice that did not cross within 180 s, even after gentle guidance, were excluded from the study. Twenty-four hours later, mice were returned to the IA room and tested for longterm memory retention. Following a 120 min acclimatization period, mice were individually placed back into the illuminated chamber of the shuttle box, facing away from the door. Mice were given 30 s to explore the illuminated chamber before the door to the dark chamber opened. The transfer latency to cross into the dark chamber was recorded and used as an indication of long-term memory. A cut-off criterion was set at 180 s. If mice did not cross within 180 s, they were removed from the chamber and given a maximal transfer latency of 180 s.
For experiments performed in non-MK-801-treated subjects, the exact same protocol was used, except subjects did not receive challenge with MK-801 prior to the training session.
Cross-maze model with MAM rats
A similar protocol was used for MAM studies in crossmaze as was used in the ketamine studies, except the dosing regimen was modified and the same cohort of animals was used for all experiments. For the acute treatment experiment, ABT-239 (0.1-1.0 mg/kg) was administered i.p. 30 min before testing. Approximately 2 wk after the completion of the acute treatment experiment, the chronic treatment experiment was initiated. Rats were evenly distributed among treatment groups based on treatment received in the acute study. ABT-239 (0.1-1.0 mg/kg) was given i.p. once per day for 14 consecutive days. The cross-maze test was performed on the 14th day of treatment 30 min after subjects received their final dose of ABT-239.
Statistical analysis
The effect of drug treatment on % alternation and total arm entries in cross-maze were analysed by one-way analysis of variance (ANOVA). Post-hoc analysis was performed using Dunnett's multiple comparison test.
For IA experiments, the effect of drug treatment on training and test day transfer latencies was analysed by non-parametric Kruskal-Wallis test. When significant main treatment effects were detected by KruskalWallis test, follow-up post-hoc analysis was performed with Mann-Whitney U test. Significance was set at p<0.05 for all experiments.
Results
Effect of ABT-239, A-431404, risperidone and olanzapine alone on spontaneous alternation behaviour in cross-maze
ABT-239
A significant main effect of treatment on total arm entries (F 3,28 =6.331, p=0.002), but not % alternation (F 3,28 =0.824, p=0.492), was revealed by one-way ANOVA. Post-hoc analysis indicated a significant reduction in total arm entries was produced by 3 mg/kg ABT-239 (p<0.01 compared to vehicle-treated group, Table 1 ). 
A-431404
There were no significant main effects of treatment on either % alternation (F 3,26 =0.493, p=0.690) or total arm entries (F 3,26 =0.573, p=0.638), as indicated by one-way ANOVA (see Table 1 and Fig. 1 b) .
Risperidone
One-way ANOVA revealed a significant main effect of treatment on total arm entries (F 3,26 =14.56, p<0.001), but not % alternation (F 3,26 =0.638, p=0.598). Post-hoc analysis indicated that a significant reduction in total arm entries was produced by 0.3 mg/kg risperidone (p<0.001 compared to the vehicle-treated group, Table 1 ). Moderate sedation was observed in subjects from this treatment group and two of eight subjects (25 %) were excluded for failing to make at least 10 arm entries.
Olanzapine A significant main effect of treatment on total arm entries (F 3,22 =5.166, p=0.007), but not % alternation (F 3,22 =0.137, p=0.937), was revealed by one-way ANOVA. Post-hoc analysis indicated that a significant reduction in total arm entries was produced by 1 mg/ kg olanzapine (p<0.01 compared to vehicle-treated group, Table 1 ). Sedation was observed in subjects treated with the high dose of 3 mg/kg olanzapine and five of eight subjects (63 %) were excluded from analysis for failing to make at least 10 arm entries (Table 1 ). The high proportion of subjects excluded in this treatment group also explains why no statistically significant effect on total arm entries was indicated by post-hoc analysis.
Effect of ABT-239, A-431404, risperidone and olanzapine on ketamine-induced spontaneous alternation behaviour impairments in cross-maze ABT-239 vs. ketamine
One-way ANOVA revealed a significant main effect of treatment on % alternation (F 4,89 =9.261, p<0.001) and total arm entries (F 4,89 =6.765, p<0.001). Post-hoc analysis indicated that ketamine significantly reduced % alternation (p<0.01, Fig. 2a ) compared to the vehicle-treated control group, indicating impaired spatial working memory. Pre-treatment with 1 and 3 mg/kg ABT-239 significantly attenuated the ketamine-induced reduction in % alternation (p<0.05, Fig. 2 a) . Ketamine also significantly increased total arm entries compared to the vehicle-treated control group (p<0.01, Table 2 ). A dose of 3 mg/kg ABT-239 attenuated the ketamine-induced increase in total arm entries (p<0.001 compared to the vehicle-treated ketamine group, respectively, Table 2 ).
A-431404 vs. ketamine
One-way ANOVA revealed a significant main effect of treatment on % alternation (F 4,42 =8.056, p<0.001). In contrast to the study with ABT-239, no significant treatment effects were observed for total arm entries. Post-hoc analysis indicated that a significant reduction in % alternation was produced by ketamine (p<0.01 compared to vehicle-treated control group, Fig. 2 b) .
Doses of 1 and 3 mg/kg A-431404 significantly increased % alternation in ketamine-treated subjects (p<0.05 and p<0.01 compared to vehicle-treated ketamine group, respectively ; Fig. 2b ).
Risperidone vs. ketamine A significant main effect of treatment on % alternation (F 4,58 =13.23, p<0.001) and total arm entries (F 4,58 = 3.953, p=0.002) was revealed by one-way ANOVA. Post-hoc analysis indicated that a significant reduction in % alternation was produced by ketamine (p<0.01 compared to the vehicle-treated control group, Fig. 2 c) . Risperidone did not attenuate the ketamine-induced impairment on % alternation at any of the doses tested (0.03-0.3 mg/kg, Fig. 2 c) . A significant increase in total arm entries was produced by ketamine (p<0.05 compared to the vehicle-treated control group, Table 2 ). The high dose of risperidone (0.3 mg/kg) significantly attenuated this ketamine-induced effect (p<0.01 vs. vehicle-treated ketamine group, Table 2 ). Three of 16 subjects (19 %) that received the dose of 0.3 mg/kg were excluded from the study for failing to make at least 10 arm entries, consistent with moderate sedation observed in these subjects.
Olanzapine vs. ketamine One-way ANOVA indicated a significant main effect of treatment on % alternation (F 4,44 =5.062, p=0.002) and arm entries (F 4,44 =3.206, p=0.022) . Ketamine produced a significant reduction in % alternation (p<0.001 vs. vehicle-treated control group, Fig. 2 d) , as revealed by post-hoc analysis. Olanzapine did not significantly attenuate the impairment on % alternation produced by ketamine at any of the doses tested (0.1-1.0 mg/kg, Fig. 2 d) . However, the mean % alternation for the 0.1 mg/kg olanzapine group was not significantly different from the vehicle-treated control group (Fig. 2 d) . Although ketamine did not significantly increase arm entries in this particular study, 1 mg/kg olanzapine produced a significant decrease in arm entries compared to the vehicle-treated ketamine group (p<0.05, Table 2 ).
Effect of ABT-239, A-431404, risperidone and olanzapine alone in IA
ABT-239
There were no significant effects of treatment on training and test day transfer latencies (H=2.678 ; p=0.444 and H=3.150 ; p=0.369, respectively) indicated by Kruskal-Wallis test (see Table 3 and Fig. 3a) .
A-431404
A significant main effect of treatment on training day (H=8.954 ; p=0.030), but not test day (H=1.360 ; p=0.715, Fig. 3 b) transfer latencies was revealed by Kruskal-Wallis test. Post-hoc analysis with MannWhitney U test indicated that a significant increase in training day transfer latency was produced by 3 mg/kg (p<0.01 vs. vehicle-treated control group, Table 3 ). However, sedation was not observed in subjects from this treatment group.
Risperidone
Kruskal-Wallis test indicated a significant main effect of treatment on training and test day (H=18.99 ; p<0.001 and H=10.15 ; p=0.017, respectively) transfer latencies. Risperidone dose-dependently increased training day transfer latencies ; 0.1 and 0.3 mg/kg produced a statistically significant effect (p<0.01 and p<0.001 vs. vehicle-treated group, respectively ; see Table 3 ), as revealed by post-hoc analysis with Mann-Whitney U test. Sedation was observed in subjects from both treatment groups during the training session. A statistically significant decrease in test day latencies was only observed for the 0.3 mg/kg treatment group (p<0.05 compared to vehicle-treated group, Fig. 3 c) .
Olanzapine A significant main effect of treatment on training and test day transfer latencies (H=16.67 ; p<0.001 and H=17.13 ; p<0.001, respectively) was indicated by Kruskal-Wallis test. Olanzapine increased training day transfer latency in a dose-dependent manner. Doses of 1 and 3 mg/kg were significantly different from the vehicle-treated group (p<0.05 and p<0.001, respectively ; Table 3 ), as revealed by post-hoc analysis with Mann-Whitney U test. Sedation was observed in subjects from both treatment groups during the training session. Olanzapine also produced a dosedependent decrease in test day transfer latencies ; statistically significant effects were indicated for 1 and 3 mg/kg (p<0.01 vs. vehicle-treated group, Fig. 3 d) .
Effect of ABT-239, A-431404, risperidone and olanzapine on MK-801-induced memory impairments in IA
ABT-239 vs. MK-801
A significant main effect of treatment on test day transfer latencies (H=12.04 ; p=0.017) was indicated by Kruskal-Wallis test. There were no significant effects of treatment on training day latencies. Post-hoc analysis with Mann-Whitney U test indicated that a significant reduction in test day transfer latency was produced by pre-training administration of 0.1 mg/kg MK-801 (p<0.01 vs. vehicle-treated control group, Fig. 4 a) , indicating an impairment in memory retention. Pre-treatment with 1 mg/kg ABT-239 significantly attenuated the deficit induced by MK-801, almost completely blocking the impairment (p<0.05 vs. MK-801-treated group, Fig. 4 a) Fig. 4b ). Pre-treatment with 1 and 3 mg/kg A-431404 significantly attenuated the MK-801-induced impairment (p<0.001 vs. MK-801-treated group, Fig. 4 b) . A dose of 3 mg/kg A-431404 also increased training day latencies compared to the vehicle-treated group (p<0.01, Table 4 ).
Risperidone vs. MK-801
Kruskal-Wallis test indicated a significant main effect of treatment on training and test day (H=29.58 ; p<0.001 and H=11.07 ; p=0.026, respectively) transfer latencies. Risperidone dose-dependently increased training day transfer latencies ; 0.3 mg/kg produced a statistically significant effect (p<0.001 vs. vehicletreated control group, Table 4), as revealed by post-hoc analysis with Mann-Whitney U test. Sedation was observed in subjects from both the 0.1 and 0.3 mg/kg treatment groups during the training session. MK-801 produced a significant reduction in test day transfer latencies (p<0.01 vs. vehicle-treated control group, Fig. 4 c) . None of the doses of risperidone tested (0.03-0.3 mg/kg) was able to attenuate the MK-801-induced deficit.
Olanzapine vs. MK-801
A significant main effect of treatment on training and test day transfer latencies (H=24.85 ; p<0.001 and H=18.09 ; p=0.001, respectively) was indicated by Kruskal-Wallis test. Olanzapine increased training day transfer latency in a dose-dependent manner. Doses of 1 and 3 mg/kg were significantly different from the vehicle-treated control group (p<0.001 and p<0.01, respectively ; Table 4), as revealed by post-hoc analysis with Mann-Whitney U test. Sedation was observed in subjects from both the 1 and 3 mg/kg treatment groups during the training session. MK-801 produced a significant reduction in test day transfer latencies (p<0.01 vs. vehicle-treated control group, Fig. 4 d) . None of the doses of olanzapine tested (0.3-3 mg/kg) attenuated the MK-801-induced deficit.
Effect of acute and chronic treatment with ABT-239 on spontaneous alternation behaviour in MAM rats tested in cross-maze
Acute treatment
One-way ANOVA revealed a significant main effect of treatment on % alternation (F 4,40 =6.417, p=0.004). Post-hoc analysis indicated that % alternation was significantly lower in vehicle-treated MAM animals compared to vehicle-treated non-MAM controls (p<0.01, Fig. 5 a) , indicating impaired spatial working memory. Acute treatment with ABT-239, at all doses tested (0.1-1.0 mg/kg), did not significantly improve % alternation in MAM animals. No significant treatment effects were observed for total arm entries (Table 5) .
Chronic treatment
A significant main effect of treatment on % alternation (F 4,43 =11.36, p<0.001) was indicated by one-way ANOVA. Vehicle-treated MAM animals showed a significant reduction in % alternations (p<0.01, Fig. 5b ) compared to vehicle-treated non-MAM controls, as determined by post-hoc analysis. Chronic treatment with 0.1 and 1.0 mg/kg ABT-239 significantly improved % alternation in MAM animals (p<0.01 vs. vehicle-treated MAM group, Fig. 5 b) . A similar trend for improvement was observed in MAM subjects treated chronically with 0.3 mg/kg, but this effect was not statistically significant. No treatment effects were observed for arm entries (Table 5) . 
Discussion
In the studies presented here, we investigated the effects of two potent and selective non-imidazole-based H 3 R antagonists in direct comparison to two widely used atypical antipsychotics in preclinical models that may have relevance to CDS. We observed that acute pre-treatment with the H 3 R antagonists ABT-239 and A-431404 significantly attenuated behavioural impairments induced by ketamine or MK-801 in two cognition assays (cross-maze and IA), which are considered to provide indications of spatial working memory and memory retention, respectively (Izquierdo et al. 2002 ; McGaugh, 1966 ; Ragozzino et al. 1996 Ragozzino et al. , 1998 . In contrast, olanzapine and risperidone failed to ameliorate ketamine and MK-801-induced memory impairments in these models. Chronic treatment with ABT-239 was also found to significantly improve spontaneous alternation behaviour in MAM rats, a putative neurodevelopmental model of schizophrenia, tested in the cross-maze model. Although several studies have demonstrated that prenatal treatment with MAM can elicit a wide range of cognitive impairments (Flagstad et al. 2005 ; Le Pen et al. 2006 ; Moore et al. 2006) , the results presented here, to our knowledge, are the first to demonstrate that working memory impairments in MAM rats can be attenuated through novel pharmaceutical intervention. It is worthwhile to note that the cross-maze impairments in MAM rats cannot be attenuated by acute or chronic treatment with risperidone (Basso et al. unpublished observations) , which is consistent with what we observed in the NMDA hypofunction models of CDS.
The results that we obtained with ABT-239 and A-431404 are consistent with the limited available literature on representative H 3 R tool antagonists in models related to CDS. These reports have demonstrated that central administration of imidazole-based Neither risperidone (c) nor olanzapine (d), at all doses tested, were able to attenuate the deficit produced by MK-801. # p<0.05, ## p<0.01, and ### p<0.001 compared to vehicle-treated group ; * p<0.05 and *** p<0.001 compared to MK-801-treated group.
antagonists, such as thioperamide and clobenpropit, can attenuate NMDAR antagonist-induced spatial working memory impairments in the radial-arm maze test (Chen et al. 1999 ; Huange et al. 2004 ; Nishiga & Kamei, 2003) . Thioperamide was also reported to attenuate MK-801-induced impairments in IA and fear conditioning (Bernaerts et al. 2004; Charlier & Tirelli, 2011) following systemic administration, but only posttraining drug administration was examined. Bardgett et al. (2010) reported attenuation of MK-801-induced working memory impairments in a delayed alternation T-maze test with systemic administration of ciproxifan. However, the same lab also reported that systemic administration of thioperamide did not attenuate MK-801-induced working memory deficits in the same T-maze task (Bardgett et al. 2009 ). To our knowledge, the results presented herein are the first to examine and directly compare systemic administration of non-imidazolebased H 3 R antagonists to atypical antipsychotics in the same preclinical cognition assays with relevance to CDS. The finding that chronic treatment with ABT-239 improved spatial working memory in MAM rats is intriguing and provides further support regarding the potential of H 3 R antagonists for the treatment of CDS. Research suggests that behavioural abnormalities in MAM rats, including cognitive impairments, may arise from disruptions in cortical and sub-cortical neuronal activity (similar to the effects produced by NMDA antagonists). For example, decreases in inhibitory GABAergic parvalbumin-containing interneurons and hyperactive neuronal activity in the hippocampus (presumably glutamatergic pyramidal neurons) have been demonstrated in MAM animals (Lodge & Grace, 2007 ; Penschuck et al. 2006) . Similarly, ketamine-induced NMDAR hypofunction results in reduced activation of critical inhibitory GABAergic interneurons (Grunze et al. 1996) , resulting in aberrant excitatory projections to vulnerable, hyper-responsive cerebrocortical glutamatergic neurons and consequential excessive glutamate release in cortical and limbic brain areas (Farber, 2003 ; Jackson et al. 2004 ; Moghaddam et al. 1997) . It would be interesting to investigate whether the cognitive-enhancing effects of H 3 antagonists in these animal models arise from normalization of hippocampal and cortical neuronal activity. It is not clear why significant improvements were observed with chronic but not acute treatment. ABT-239 did not accumulate in the brain following multi-day dosing (data not shown), so the divergence of effects is likely not the result of increased CNS drug exposure. Since the cognitive impairments in MAM animals are borne from disease-relevant pathophysiological underpinnings, rather than transient pharmacological manipulations such as those induced by ketamine, repeated dosing may be required for functional improvements in cognition.
In contrast to the positive effects observed with ABT-239 and A-431404, the atypical antipsychotics risperidone and olanzapine were unable to ameliorate memory impairments induced by ketamine and MK-801 in the studies presented herein. It is well known that risperidone and olanzapine can produce sedative effects in humans (Conley & Meltzer, 2000 ; Miller, 2004) . Also, it is possible that sedation may negatively impact cognitive function. Patients receiving antipsychotic treatments frequently complain of mental 'cloudiness ' and an inability to think straight (McGrath & Tempier, 2005) . In preclinical studies it is often hard to separate sedative effects from impairment-like effects on cognitive endpoints. In the ketamine cross-maze studies, it is unlikely that the lack of effect with risperidone and olanzapine is due to sedative effects, given that these two drugs only normalized total arm entries rather than bringing them below control group levels. Furthermore, neither risperidone nor olanzapine impaired % alternation in non-ketamine-treated subjects despite producing significant reductions in total arm entries at high doses. For IA studies, it is less clear to what degree sedative effects may have contributed to the lack of efficacy. Dose-dependent increases in training day transfer latencies were produced by risperidone and olanzapine when given alone or in combination with MK-801. These effects were highly correlated with reductions in test day transfer latencies in naive subjects (r=x0.9611, p=0.0389 for olanzapine and r= x0.9281, p=0.0719 for risperidone), indicating that memory impairments were produced at doses that also cause marked sedation. This suggests that sedative effects may contribute, at least partially, to the lack of attenuation against MK-801-induced impairments in IA, particularly for those doses that perturbed performance in non-MK-801-treated mice. For the lower doses of risperidone and olanzapine tested that did not affect training day latencies, it is unlikely that insufficient target coverage explains the lack of efficacy as numerous studies have previously demonstrated that similar (and lower) doses are capable of attenuating both amphetamine and NMDAR antagonistinduced hyperlocomotion in rodents (Corbett et al. 1995 ; Gleason & Shannon, 1997) . Ultimately, the current results are generally in agreement with multiple reports that observed no significant effects against NMDAR antagonist-induced cognitive impairments in preclinical models (Enomoto et al. 2008 ; Ishiyama 2007 ; McKibben et al. 2010 ; Roberts et al. 2010 ; although efficacy has been reported by others, see Barak & Weiner, 2011 for review) and are predictive of the clinical situation wherein atypical antipsychotics generally fail to improve cognitive impairments in schizophrenia patients (Keefe et al. 2007 ; Lublin et al. 2005) .
Although the cognition models used here are more rudimentary than those being pursued by such efforts as CNTRICS (Barch et al. 2009 ), spontaneous alternation and IA are established and well-validated endpoints for assessing pharmacological effects on cognition in rodents (Gold, 1986 ; Myhrer, 2003) and cover two cognitive constructs identified at CNTRICS (working memory and long-term memory ; Carter et al. 2008) . Spontaneous alternation behaviour is suggested to be dependent on proper functioning of the prefrontal cortex and the hippocampus (for review, see Lalonde, 2002) , while IA is thought to primarily rely on the hippocampus (Izquierdo et al. 2002) and dysfunctions in these brain areas are strongly implicated in the aetiology of CDS (Antonova et al. 2004) . Admittedly, there are limitations with attempting to model CDS, a uniquely 'human ' psychopathology, in rodents preclinically. For example, cognitive impairments induced by acute pharmacological manipulation with MK-801 or ketamine treatment may not be identical to NMDAR hypofunction in schizophrenia. In MAM rats, anatomical and behavioural changes may be more severe than those occurring in patients and the absence of a developmental delay with the emergence of behavioural impairments (Hazane et al. 2009 ) does not accurately recapitulate the postadolescent onset of disease in humans. Despite these inherent limitations, the positive signals observed with ABT-239 and A-431404 in the studies presented herein provide some support for the potential utility of H 3 R antagonists for the treatment of CDS.
The mechanisms underlying the effects observed with ABT-239 and A-431404 in the current studies are not well understood. One possibility may be increased release of acetylcholine and subsequent activation of cholinergic systems in brain areas critical for neurocognition. Functioning as a pre-synaptic heteroreceptor on non-histaminergic neurons, the H 3 receptor can modulate the synthesis and release of acetylcholine (Blandina et al. 1996) . Inhibition of H 3 heteroreceptors on cholinergic fibres via selective H 3 R antagonists can cause the subsequent release of acetylcholine in the prefrontal cortex and hippocampus (Brioni et al. 2010 ), brain regions critical for learning and memory that are disrupted in schizophrenia patients (Antonova et al. 2004) . ABT-239 and A-431404 have been reported to attenuate spatial learning and memory impairments induced by the muscarinic acetylcholine receptor antagonist scopolamine , indicating functional engagement with cholinergic pathways involved in neurocognition. Furthermore, microdialysis data indeed indicate that ABT-239 increases the release of acetylcholine in the prefrontal cortex, and to a lesser degree in the hippocampus, at doses that were efficacious against ketamine-and MK-801-induced memory impairments in the present studies (1-3 mg/kg ; Fox et al. 2005) . The increase in synaptic acetylcholine levels in the brain, produced by inhibition of H 3 heteroreceptors, may thereby stimulate nicotinic and muscarinic acetylcholine receptors, which also play critical roles in memory and attention (Graef et al. 2011) .
Histamine is well known to modulate attention and cognition, as well as wakefulness, by interacting with H 1 , H 2 and H 3 G protein-coupled receptors in the brain (Hancock & Fox, 2004 ; Passani et al. 2000) . Presynaptic H 3 auto-receptors regulate the synthesis and release of histamine (Arrang et al. 1983 ) and provide a feedback loop for maintaining histamine levels in the brain. Antagonism of H 3 auto-receptors causes the release of histamine and this has been demonstrated functionally with ABT-239 in rat cortical synaptosomes . Like the effects observed with H 3 R antagonists, central administration of histamine has been shown to similarly attenuate spatial working memory deficits induced by MK-801 in the radial-arm maze test (Chen et al. 1999 ; Xu et al. 2005) , suggesting that H 3 R antagonists may produce procognitive effects in these models through enhancing histamine release. Huang et al. (2004) observed that pyrilamine, an H 1 antagonist, blocked the attenuating effect of clobenpropit on MK-801-induced working memory impairments in the radial-arm maze test, indicating a role for the H 1 receptor in mediating the memory-improving effects produced by histamine.
In summary, the results from the studies presented herein suggest that H 3 R antagonists may have utility for the treatment of CDS. Several H 3 R antagonists have advanced to phase 2 studies for CDS. The results from these proof-of-concept studies will be critical, not only for the validation of the target but also for schizophrenia patients who suffer from debilitating and progressive cognitive dysfunction, which are not adequately treated with antipsychotic treatment.
